(2,4,5-Trioxopyrrolidin-3-yl) 2-[2-(2,4,5-trioxopyrrolidin-3-yl)oxycarbonyloxyethylsulfonyl]ethyl carbonate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: (2,4,5-Trioxopyrrolidin-3-yl) 2-[2-(2,4,5-trioxopyrrolidin-3-yl)oxycarbonyloxyethylsulfonyl]ethyl carbonate
• 英文别名: (2,4,5-trioxopyrrolidin-3-yl) 2-[2-(2,4,5-trioxopyrrolidin-3-yl)oxycarbonyloxyethylsulfonyl]ethyl carbonate
• 化学式: C₁₄H₁₂N₂O₁₄S
• 分子量: 464.32
• InChiKey: BEYSSYIAIQPNRS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  31
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  240
• 氢给体数：
  2
• 氢受体数：
  14

文献信息

• ANTIGEN-BINDING MOLECULE FOR PROMOTING CLEARANCE FROM PLASMA OF ANTIGEN COMPRISING SACCHARIDE CHAIN RECEPTOR-BINDING DOMAIN
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：EP2765192A1

  公开（公告）日：2014-08-13

  Disclosed are an antigen-binding molecule containing a sugar chain receptor-binding domain and having a weak antigen-binding activity in the pH of early-stage endosome compared to the antigen-binding activity in the pH of plasma; a pharmaceutical composition containing the antigen-binding molecule; and a method for producing these. Use of the antigen-binding molecule of the invention enables to promote uptake of an antigen into a cell and increase the number of antigens that a single antibody molecule can bind. Administration of the antibody enables to reduce the number of antigens in plasma more and more and improve pharmacokinetics of the antibody.

  本发明公开了一种抗原结合分子，该分子含有糖链受体结合域，与血浆 pH 值中的抗原结合活性相比，该分子在早期内质体 pH 值中的抗原结合活性较弱；一种含有该抗原结合分子的药物组合物；以及生产这些药物组合物的方法。使用本发明的抗原结合分子可促进细胞对抗原的吸收，并增加单个抗体分子可结合的抗原数量。使用本发明的抗体可使血浆中的抗原数量越来越少，并改善抗体的药代动力学。
• ANTIGEN-BINDING MOLECULE FOR PROMOTING CLEARANCE FROM PLASMA OF ANTIGEN COMPRISING SUGER CHAIN RECEPTOR-BINDING DOMAIN
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：US20150299313A1

  公开（公告）日：2015-10-22

  Disclosed are an antigen-binding molecule containing a sugar chain receptor-binding domain and having a weak antigen-binding activity in the pH of early-stage endosome compared to the antigen-binding activity in the pH of plasma; a pharmaceutical composition containing the antigen-binding molecule; and a method for producing these. Use of the antigen-binding molecule of the invention enables to promote uptake of an antigen into a cell and increase the number of antigens that a single antibody molecule can bind. Administration of the antibody enables to reduce the number of antigens in plasma more and more and improve pharmacokinetics of the antibody.